Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| monoclonal antibodies | 5769 | None |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Nipocalimab is a human IgG1 monoclonal antibody that binds to the neonatal Fc receptor (FcRn) at the IgG binding site. By binding to FcRn, nipocalimab blocks the interaction of FcRn with IgG, resulting in increased degradation of circulating IgG and reduced serum IgG concentrations.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 28, 2025 | EMA | Janssen Cilag International NV | |
| April 29, 2025 | FDA | Johnson & Johnson | |
| April 29, 2025 | PMDA | Janssen Pharmaceutical K.K. |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L04AL03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Neonatal fragment crystallizable receptor (FcRn) inhibitors |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Myasthenia gravis | indication | 91637004 | DOID:437 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| IgG receptor FcRn large subunit p51 | Membrane receptor | BINDING AGENT | Kd | 9.68 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| 2211985-36-1 | SECONDARY_CAS_RN |
| CHEMBL4594310 | ChEMBL_ID |
| C000731839 | MESH_SUPPLEMENTAL_RECORD_UI |
| 13876 | IUPHAR_LIGAND_ID |
| DB16257 | DRUGBANK_ID |
| 4043944 | VANDF |
| 4043945 | VANDF |
| C5418863 | UMLSCUI |
| CHEBI:757809 | CHEBI |
| 11215 | INN_ID |
| D11666 | KEGG_DRUG |
| 394865 | MMSL |
| 44052 | MMSL |
| d10279 | MMSL |
| 020093 | NDDF |
| 87M90CV8NC | UNII |
| 2712692 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| IMAAVY | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57894-800 | INJECTION, SOLUTION, CONCENTRATE | 185 mg | INTRAVENOUS | BLA | 28 sections |
| IMAAVY | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57894-801 | INJECTION, SOLUTION, CONCENTRATE | 185 mg | INTRAVENOUS | BLA | 28 sections |